Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms

類似資料

• 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
  著者:: Kaunitz, Andrew M., 等
  出版事項: (2020)
• Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
  著者:: Kagan, Risa, 等
  出版事項: (2018)
• SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
  著者:: Constantine, Ginger, 等
  出版事項: (2019)
• Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
  著者:: Mirkin, Sebastian, 等
  出版事項: (2020)
• Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
  著者:: Constantine, Ginger D., 等
  出版事項: (2019)